US 11,054,423 B2
Antibody-mediated neutralization of ebolaviruses
James E. Crowe, Jr., Nashville, TN (US); Andrew I. Flyak, Nashville, TN (US); Alexander Bukreyev, Galveston, TX (US); and Philipp Ilinykh, Galveston, TX (US)
Assigned to VANDERBILT UNIVERSITY, Nashville, TN (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by VANDERBILT UNIVERSITY, Nashville, TN (US); and THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Feb. 13, 2020, as Appl. No. 16/790,658.
Application 16/790,658 is a division of application No. 15/561,193, granted, now 10,620,204, previously published as PCT/US2016/024296, filed on Mar. 25, 2016.
Claims priority of provisional application 62/138,522, filed on Mar. 26, 2015.
Prior Publication US 2020/0200749 A1, Jun. 25, 2020
Int. Cl. G01N 33/569 (2006.01); A61K 39/42 (2006.01); C07K 16/10 (2006.01); G01N 33/577 (2006.01); A61K 39/395 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC G01N 33/56983 (2013.01) [A61K 39/395 (2013.01); A61K 39/42 (2013.01); C07K 16/10 (2013.01); G01N 33/577 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/08 (2013.01)] 12 Claims
 
1. A method of treating a subject infected with Ebolavirus, or reducing the likelihood of infection of a subject at risk of contracting Ebolavirus, comprising delivering to said subject an antibody specifically binding ebolavirus glycoprotein or an antigen binding fragment thereof having heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOS: 91, 92 and 93, and light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NO: 347, 348 and 349.